Fifth consecutive quarter of profitability * Net sales for the period of January to September rose by 13 percent to SEK 62.1 million (55.1), of which the third quarter accounted for SEK 20.8 million (21.1). * The operating profit for the period was SEK 6.3 million (0.1) and for the third quarter SEK 3.6 million (3.8). * Earnings per share for the period amounted to SEK 0.25 (-0.01). For the third quarter the earnings per share were SEK 0.14 (0.16). * Cash and cash equivalents amounted to SEK 11.3 million (16.2) at the end of the interim period. Important events during the quarter * The exclusive distribution agreement with Sysmex Europe was extended until 2010. * Official approval to market the analyzer CellaVision® DM in Japan was received. * A reference laboratory chain in Canada purchased CellaVision DM96 instruments for two laboratories. * The application for body fluids was approved for sale in Canada - the first orders were received. CellaVision in summary Jan 1- Jan 1- Full year (MSEK) Q3 2008 Q3 2007 Sep 30, Sep 30, 2007 2008 2007 Net sales 20.8 21.1 62.1 55.1 74.6 Gross profit 16.6 11.4 42.4 31.2 45.3 Operating result 3.6 3.8 6.3 0.1 3.1 Net result 3.4 3.7 6.0 -0.2 2.6 Cash flow -5.6 7.5 -5.0 -0.5 -0.4 CEO's comment"It is exciting to report a positive result for the fifth quarter in a row - a reflection of our steady sales growth. The establishment of our own sales organisation in the US is progressing according to plan, and I am hoping to see some results from our investment before the end of the year. At the same time our partnership with Sysmex, our distributor in the US, is continuously successful. The individual quarters are difficult to compare because we are dependent on the distributor's sales success and inventory levels. The revenue from the various geographical markets varies between the periods, which is entirely normal in this industry. Coupled with the dollar exchange rate, the positive result of the third quarter is mainly due to sales in North America. We are however expecting a more even distribution between Europe and North America for the full year." For further information, please contact: Yvonne Mårtensson, CEO. Phone: 0708 33 77 82, e-mail: yvonne.martensson@cellavision.se Johan Wennerholm, CFO. Phone: 0708 33 81 68, e-mail: johan.wennerholm@cellavision.se Download the report by pressing the link below.
CELLAVISION AB (publ) Interim report for the period January 1 - September 30, 2008
| Quelle: CellaVision